Jeil Pharma Holdings Inc (002620.KS)
KRW 7990.0
(-3.5%)
KRW 7990.0
(-3.5%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 33.47 Billion KRW | 134.12% |
| 2022 | -72.71 Billion KRW | -771.66% |
| 2021 | 6.14 Billion KRW | -75.69% |
| 2020 | 43.33 Billion KRW | 69.78% |
| 2019 | -78.88 Billion KRW | 106.23% |
| 2018 | 12.6 Billion KRW | 70.17% |
| 2017 | 5.76 Billion KRW | -67.33% |
| 2016 | 6.13 Billion KRW | -11.13% |
| 2015 | 21.61 Billion KRW | 18.83% |
| 2014 | 19.59 Billion KRW | 70.92% |
| 2013 | 10.1 Billion KRW | -41.88% |
| 2012 | 19.46 Billion KRW | -49.59% |
| 2011 | 38.79 Billion KRW | -15.08% |
| 2010 | 49.59 Billion KRW | 1.78% |
| 2009 | 47.62 Billion KRW | 57.65% |
| 2008 | 30.91 Billion KRW | 2.2% |
| 2007 | 30.23 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -10.78 Billion KRW | -567.83% |
| 2024 Q1 | 1.44 Billion KRW | 113.15% |
| 2023 Q3 | 3.49 Billion KRW | -27.73% |
| 2023 Q2 | 4.83 Billion KRW | -80.12% |
| 2023 Q4 | 1.9 Billion KRW | -45.57% |
| 2023 FY | - KRW | 134.12% |
| 2023 Q1 | 24.31 Billion KRW | 131.89% |
| 2022 Q3 | 2.9 Billion KRW | -8.92% |
| 2022 Q2 | 3.19 Billion KRW | 621.56% |
| 2022 Q1 | -611.99 Million KRW | 85.53% |
| 2022 FY | - KRW | -771.66% |
| 2022 Q4 | -76.25 Billion KRW | -2722.99% |
| 2021 Q4 | -4.23 Billion KRW | -198.16% |
| 2021 Q1 | 4.92 Billion KRW | -70.17% |
| 2021 Q2 | 5.53 Billion KRW | 12.34% |
| 2021 Q3 | 4.3 Billion KRW | -22.1% |
| 2021 FY | - KRW | -75.69% |
| 2020 Q4 | 16.51 Billion KRW | 211.25% |
| 2020 FY | - KRW | 69.78% |
| 2020 Q1 | 11.78 Billion KRW | 492.03% |
| 2020 Q2 | 9.73 Billion KRW | -17.34% |
| 2020 Q3 | 5.3 Billion KRW | -45.53% |
| 2019 Q2 | 8.63 Billion KRW | 94.35% |
| 2019 Q1 | 4.44 Billion KRW | -47.74% |
| 2019 Q4 | 1.98 Billion KRW | -74.25% |
| 2019 Q3 | 7.72 Billion KRW | -10.51% |
| 2019 FY | - KRW | 106.23% |
| 2018 FY | - KRW | 70.17% |
| 2018 Q4 | 8.5 Billion KRW | 835.53% |
| 2018 Q3 | 908.92 Million KRW | -61.51% |
| 2018 Q2 | 2.36 Billion KRW | 7.35% |
| 2018 Q1 | 2.19 Billion KRW | 365.75% |
| 2017 Q2 | 2.79 Billion KRW | -27.07% |
| 2017 FY | - KRW | -67.33% |
| 2017 Q1 | 3.82 Billion KRW | -65.43% |
| 2017 Q3 | 2.38 Billion KRW | -14.7% |
| 2017 Q4 | -827.82 Million KRW | -134.78% |
| 2016 Q1 | 5.39 Billion KRW | 0.0% |
| 2016 Q3 | 3.48 Billion KRW | -13.36% |
| 2016 Q4 | 11.06 Billion KRW | 217.92% |
| 2016 Q2 | 4.01 Billion KRW | -25.53% |
| 2016 FY | - KRW | -11.13% |
| 2015 FY | - KRW | 18.83% |
| 2015 Q4 | - KRW | -100.0% |
| 2015 Q3 | 6.04 Billion KRW | -24.55% |
| 2015 Q2 | 8 Billion KRW | 95.42% |
| 2015 Q1 | 4.09 Billion KRW | -6.71% |
| 2014 Q2 | 5.88 Billion KRW | 759.42% |
| 2014 Q1 | 684.45 Million KRW | 1819.04% |
| 2014 FY | - KRW | 70.92% |
| 2014 Q4 | 4.39 Billion KRW | -9.05% |
| 2014 Q3 | 4.82 Billion KRW | -17.9% |
| 2013 Q3 | 200.57 Million KRW | -81.75% |
| 2013 Q4 | 35.66 Million KRW | -82.22% |
| 2013 FY | - KRW | -41.88% |
| 2013 Q1 | 1.51 Billion KRW | 38.82% |
| 2013 Q2 | 1.09 Billion KRW | -27.52% |
| 2012 Q4 | 1.09 Billion KRW | -72.52% |
| 2012 FY | - KRW | -49.59% |
| 2012 Q1 | 7.56 Billion KRW | 522.31% |
| 2012 Q2 | 4.19 Billion KRW | -44.57% |
| 2012 Q3 | 3.97 Billion KRW | -5.25% |
| 2011 FY | - KRW | -15.08% |
| 2011 Q4 | 1.21 Billion KRW | -93.22% |
| 2011 Q3 | 17.92 Billion KRW | 153.1% |
| 2011 Q2 | 7.08 Billion KRW | -50.16% |
| 2011 Q1 | 14.21 Billion KRW | 40.42% |
| 2010 Q2 | 17.51 Billion KRW | 84.93% |
| 2010 FY | - KRW | 1.78% |
| 2010 Q4 | 10.12 Billion KRW | -18.7% |
| 2010 Q3 | 12.44 Billion KRW | -28.93% |
| 2010 Q1 | 9.47 Billion KRW | -8.32% |
| 2009 Q1 | 10.75 Billion KRW | 84.15% |
| 2009 Q2 | 13.91 Billion KRW | 29.36% |
| 2009 Q3 | 13.68 Billion KRW | -1.65% |
| 2009 Q4 | 10.33 Billion KRW | -24.51% |
| 2009 FY | - KRW | 57.65% |
| 2008 Q3 | 7.82 Billion KRW | -26.01% |
| 2008 Q2 | 10.57 Billion KRW | 59.02% |
| 2008 Q1 | 6.64 Billion KRW | -17.75% |
| 2008 Q4 | 5.84 Billion KRW | -25.32% |
| 2008 FY | - KRW | 2.2% |
| 2007 Q1 | 5.77 Billion KRW | 0.0% |
| 2007 Q4 | 8.08 Billion KRW | -0.61% |
| 2007 Q3 | 8.13 Billion KRW | -1.22% |
| 2007 Q2 | 8.23 Billion KRW | 42.58% |
| 2007 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -589.041% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 76.319% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 152.277% |
| HANDOK Inc. | 35.06 Billion KRW | 4.536% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 3329.473% |
| Yuhan Corporation | 127.43 Billion KRW | 73.731% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 10.781% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 254.355% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 89.647% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -570.817% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -121.427% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -878.549% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -639.57% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 5.666% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -589.041% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 281.227% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -410.696% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 167.914% |
| JW Holdings Corporation | 187.88 Billion KRW | 82.183% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 165.346% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 88.197% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 62.48% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 190.312% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -153.421% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -183.026% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -79.449% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -589.041% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 39.105% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 79.701% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 62.48% |
| Yuhan Corporation | 127.43 Billion KRW | 73.731% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -337.603% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 56.541% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 62.48% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 8.622% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 52.704% |
| CKD Bio Corp. | -1.63 Billion KRW | 2153.179% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 32.77% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -2.808% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 9.058% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 190.312% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 46.253% |
| Boryung Corporation | 114.28 Billion KRW | 70.709% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 209.512% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -121.427% |
| JW Lifescience Corporation | 50.82 Billion KRW | 34.14% |